Login to Your Account

FDA Committee Meeting to Illuminate Vanda Sleep Drug

By Catherine Shaffer
Staff Writer

Tuesday, November 12, 2013
Briefing documents released ahead of Thursday’s FDA advisory committee meeting regarding Vanda Pharmaceuticals Inc.’s therapy for non-24-hour disorder, tasimelteon, revealed an ongoing disconnect between the sponsor and agency regarding clinical endpoints for the disorder, whose symptoms can be difficult to pin down.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription